Cost-effectiveness of hypertension treatment in Catalona (Spain)

Medicina Clinica

Volumn 118, Issue 6, 2002, Pages 211-216

  Plans Rubió, Pedro ^a   Tresserras Gaju, Ricard ^a   Navas Alcalá, Encarna ^a   Pardell Alentá, Helios ^b  

^a Department de Sanitat ^*  (Spain)

^b Hospital Cruz Roja   (Spain)

Author keywords

Cardiovascular disease prevention; Cost effectiveness; Evaluative studies; Hypertension treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; NIFEDIPINE; PRAZOSIN; PROPRANOLOL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; HYPERTENSION; MALE; SPAIN; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED;

ADULT; AGED; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SPAIN;

EID: 0037160667     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(02)72338-5     Document Type: Article

References (30)

1. Control de la hipertensión arterial en España
2. British Hypertension Society guidelines for hypertension management 1999: Summary
3. 1993 Guidelines for the management of mild hypertension: Memorandum from the WHO/ISH Meeting
4. The Framingham study: An epidemiological investigation of cardiovascular disease
5. The Framingham study. The epidemiology of atherosclerotic disease
6. Epidemiología de la hipertensión arterial en la población adulta de Cataluña
7. El control de la hipertensió arterial a Catalunya
8. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies for the regression dilution bias
9. Allocation of resources to manage hypertension
10. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension
11. Hipertensión arterial
12. The 1988 report of the Joint Committee on Detection, Evaluation and Treatment of High Blood Pressure
13. Informe económico-funcional de las Instituciones Sanitarias
14. The probability of developing certain cardiovascular disease in eight years at specified values of some characteristics
15. Cost-effectiveness in health and medicine
16. Principles of economic appraisal in health care
17. Grupo de estudio sobre el abordaje farmacológico de la hipertensión en atención primaria (AFHAP). Selección del tratamiento farmacológico de la hipertensión arterial en atención primaria
18. Randomised, double blind, multicentre comparison of hydrochlorotiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: Results of the HANE study
19. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo
20. Cost-effectiveness of interventions to prevent or treat coronary heart disease
21. The cost-effectiveness of the switch towards more expensive antihypertensive drugs
22. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the primary prevention of coronary heart disease. Evaluative study carried out in Spain
23. Cost-effectiveness of cardiovascular prevention programmes in Spain
24. The cost-effectiveness of counselling smokers to quit
25. Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking
26. Estudio coste-efectividad de los tratamientos farmacológicos hipolipemiantes
27. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease
28. The cost-effectiveness of HMG-CoA reductase inhibitors to preventcoronary heart disease
29. Cost-effectiveness analysis of lipid-modification therapy in Canada: Comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease